OptiNose (NASDAQ:OPTN) Downgraded by Lake Street Capital to “Hold”

OptiNose (NASDAQ:OPTN) was downgraded by research analysts at Lake Street Capital from a “buy” rating to a “hold” rating in a report released on Thursday, Marketbeat.com reports.

Separately, HC Wainwright boosted their price target on OptiNose from $5.00 to $18.00 and gave the company a “buy” rating in a research note on Friday, January 3rd.

OptiNose Stock Up 3.4 %

OPTN stock opened at $6.00 on Thursday. The company has a market cap of $60.36 million, a PE ratio of -1.43 and a beta of -0.30. The business has a 50-day simple moving average of $5.81 and a 200 day simple moving average of $8.21. OptiNose has a 52 week low of $4.82 and a 52 week high of $26.40.

Insider Activity at OptiNose

In other OptiNose news, CEO Ramy A. Mahmoud sold 6,376 shares of OptiNose stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $5.29, for a total value of $33,729.04. Following the transaction, the chief executive officer now owns 126,931 shares in the company, valued at $671,464.99. The trade was a 4.78 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 8,213 shares of company stock valued at $43,643 over the last quarter. 2.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of OPTN. GSA Capital Partners LLP bought a new position in OptiNose in the third quarter valued at about $61,000. State Street Corp grew its position in OptiNose by 14.2% in the third quarter. State Street Corp now owns 341,303 shares of the company’s stock valued at $229,000 after acquiring an additional 42,500 shares during the last quarter. Geode Capital Management LLC grew its position in OptiNose by 33.7% in the third quarter. Geode Capital Management LLC now owns 1,298,333 shares of the company’s stock valued at $870,000 after acquiring an additional 326,918 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in OptiNose by 5.3% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,075,638 shares of the company’s stock valued at $2,061,000 after acquiring an additional 155,329 shares during the last quarter. Finally, Acorn Capital Advisors LLC bought a new position in OptiNose in the fourth quarter valued at about $2,824,000. Institutional investors own 85.60% of the company’s stock.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.